Evidence map›Paper›PMID 41309950›Full record

ArticleScientific reports2025

Characterisation of human in vitro tumour-associated macrophage models to define translational relevance.

Arthur Dyer, Rebecca Dudley, Shreya Ahuja, Clara Alsinet, Pawan Poudel, Georgina Bowyer, Kalvin Sahota, Saly Songvilay, Des C Jones, Matthew Glover and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arthur Dyer *Early Oncology, R&D, AstraZeneca, Cambridge, UK.
Rebecca Dudley *Early Oncology, R&D, AstraZeneca, Cambridge, UK.
Shreya AhujaDynamic Omics, Centre for Genomics Research, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
Clara AlsinetOncology Bioinformatics, AstraZeneca, Barcelona, Spain.
Pawan PoudelOncology Bioinformatics, AstraZeneca, Cambridge, UK.
Georgina BowyerEarly Oncology, R&D, AstraZeneca, Cambridge, UK.
Kalvin SahotaEarly Oncology, R&D, AstraZeneca, Cambridge, UK.
Saly SongvilayEarly Oncology, R&D, AstraZeneca, Cambridge, UK.
Des C JonesEarly Oncology, R&D, AstraZeneca, Cambridge, UK.
Matthew GloverDynamic Omics, Centre for Genomics Research, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
Sonja HessDynamic Omics, Centre for Genomics Research, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA.
Elina Timosenko *Early Oncology, R&D, AstraZeneca, Cambridge, UK.
Simon J Dovedi *Early Oncology, R&D, AstraZeneca, Cambridge, UK. simon.dovedi@astrazeneca.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour-associated macrophages (TAMs) are key components of the tumour microenvironment with a demonstrated ability to modulate anti-tumour T-cell responses and immunotherapy outcomes. With increasing realisation that the M1/M2 paradigm does not reflect the complexity of macrophage phenotypes in cancer patients, an urgent need has arisen to develop improved, translatable in vitro models for human TAMs. To address this gap, we have screened conditioned media from a panel of tumour cell lines for their ability to induce suppressive marker upregulation on human monocyte-derived macrophages, as well as active T-cell immunosuppression. We performed secretome characterization of these tumour-conditioned media (TCM) to shed light on cancer cell-derived soluble factors that may contribute to TAM polarisation. Furthermore, we characterized the proteomic and transcriptomic signatures of macrophages exposed to either TCM or primary ascites fluid from ovarian cancer patients and performed bioinformatics analysis to determine the most translationally relevant models of TAMs. In summary, our work provides mechanistic insights on tumour-macrophage crosstalk in the context of establishing suppressive TAM phenotypes and addresses the long-standing gap of defining translationally relevant human in vitro TAM models.

Indexed as

MacrophagesOvarian NeoplasmsTumor-Associated MacrophagesCell Line, TumorCulture Media, ConditionedFemaleHumansProteomicsTranscriptomeTumor MicroenvironmentCulture Media, Conditioned

Identifiers

PMID41309950
PMCPMC12753636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.